

## Index

Note: Page numbers of article titles are in boldface type.

- ACETAMINOPHEN, therapeutic monitoring of, 573-578  
toxic effects, 575-577  
Affective disorders, drug therapy for, 541-545  
Alcoholism, laboratory diagnosis, 582  
Aminoglycoside(s), toxic effects, 592-593  
Amitriptyline, therapeutic monitoring of, 541-544  
Antimicrobial agents, therapeutic monitoring of, 585-597  
toxic effects, 587-595  
Arrhythmias, drug therapy for, 501-522, 523-533  
Aspirin, therapeutic monitoring of, 567-573
- BACTERIAL colonization, laboratory diagnosis, 595-596
- CARBAMAZEPINE, therapeutic monitoring of, 484-486  
Cardiac glycosides. See *Digoxin* and *Digitoxin*.  
Cephalosporin(s), toxic effects, 589  
Chloramphenicol, toxic effects, 590-591  
Chlorpromazine, therapeutic monitoring of, 551-553  
Chromatography, in therapeutic drug monitoring, 444-445, 460-463. See also under specific methods.  
Clindamycin, toxic effects, 590  
Colistin, toxic effects, 593  
Compliance, in therapeutic drug monitoring, 469  
Congestive heart failure, drug therapy for, 523-533  
Cyanide, red cell, therapeutic monitoring of, 536
- DEPRESSION, drug therapy for, 541-544  
Desipramine, therapeutic monitoring of, 541-544  
Digitoxin, therapeutic monitoring of, 531-533  
Digoxin, therapeutic monitoring of, 525-530  
toxic effects, 531  
Disopyramide, therapeutic monitoring of, 509-511  
toxic effects, 510-511  
Doxepin, therapeutic monitoring of, 541-544  
Drug(s). See also under specific drugs.  
antiarrhythmic, investigational, 516-519  
therapeutic monitoring of, 501-522  
antidepressant, therapeutic monitoring of, 541-545  
antiepileptic, therapeutic monitoring of, 479-500  
antimicrobial, therapeutic monitoring of, 585-597  
antipsychotic, therapeutic monitoring of, 547-557  
cardiac glycosides, therapeutic monitoring of, 523-539  
pharmacokinetics, 469-474  
therapy, monitoring of, 439-597  
vasoactive, therapeutic monitoring of, 534-537
- ENZYME immunoassay(s), heterogeneous, in therapeutic drug monitoring, 456-457  
homogeneous, in therapeutic drug monitoring, 456  
Enzyme Multiplied Immunoassay Technique (EMIT), in monitoring antiepileptics, 490-491  
in monitoring theophylline, 566-567  
in therapeutic drug monitoring, 456  
Epilepsy, drug therapy for, 479-500  
Erythromycin, toxic effects, 590  
Ethambutol, toxic effects, 595  
Ethanol, therapeutic monitoring of, 581-583  
Ethanol intoxication, 581-582  
Ethosuximide, therapeutic monitoring of, 489-490
- FLUOROIMMUNOASSAY(s), heterogeneous, in therapeutic drug monitoring, 458-459  
homogeneous, in therapeutic drug monitoring, 458

- Fluphenazine, therapeutic monitoring of, 554-555
- GAS-LIQUID chromatography, in monitoring acetaminophen, 578  
in monitoring antiepileptics, 490-491  
in monitoring ethanol, 582-583  
in monitoring theophylline, 566-567  
in therapeutic drug monitoring, 461-462
- Glycoside, cardiac. See *Digoxin* and *Digitoxin*.
- HEART failure, congestive, drug therapy for, 523-533
- Hepatic necrosis, acetaminophen-induced, 575-576
- High performance liquid chromatography (HPLC), in monitoring acetaminophen, 578  
in monitoring antiepileptics, 490-491  
in monitoring salicylate, 573  
in monitoring theophylline, 566-567  
in therapeutic drug monitoring, 462
- Hypotensive agents, therapeutic monitoring of, 534-537
- IMPRAMINE, therapeutic monitoring of, 541-544
- Immunoassay(s), in therapeutic drug monitoring, 444-445, 453-460. See also under specific methods.
- Inflammatory disease, drug therapy for, 567-573
- Isoniazid, toxic effects, 595-596
- LABORATORY, equipment, in therapeutic drug monitoring, 442-444  
service, organization of, 439-450  
technology, in therapeutic drug monitoring, 451-466
- Laboratory tests, in therapeutic drug monitoring, 451-466
- Lidocaine, therapeutic monitoring of, 511-513  
toxic effects, 512-513
- Light-scatter immunoassay(s), in therapeutic drug monitoring, 459-460
- Lithium, therapeutic monitoring of, 544-545  
toxic effects, 544-545
- Liver, necrosis, acetaminophen-induced, 575-576
- MANIA, drug therapy for, 544-545
- Metronidazole, toxic effects, 594
- N-ACETYL-CYSTEINE (NAC), as antidote, 577
- N-acetylprocainamide (NAPA), therapeutic monitoring of, 507-509
- Nalidixic acid, toxic effects, 594
- Nitrofurantoin, toxic effects, 594
- Nitroglycerin, therapeutic monitoring of, 536-537
- Nitroprusside, therapeutic monitoring of, 534-536  
toxic effects, 535
- Nortriptyline, therapeutic monitoring of, 541-544
- OVERDOSE, of acetaminophen, 575-577  
of alcohol, 582-583  
of salicylate, 570-572
- Oxolinic acid, toxic effects, 594
- PARACETAMOL. See *Acetaminophen*.
- Particle aggregation immunoassay(s), in therapeutic drug monitoring, 460
- Penicillin(s), toxic effects, 588-589
- Pharmacokinetics, of drugs, 469-474
- Phenobarbital, therapeutic monitoring of, 483-484
- Phenothiazine(s), therapeutic monitoring of, 547-557  
toxic effects, 555
- Phenylethyl malondiamine (PEMA), therapeutic monitoring of, 488-489
- Phenytoin, therapeutic monitoring of, 480-483, 513-514  
toxic effects, 514
- Poisoning, drug. See under specific drugs.
- Polymyxin, toxic effects, 593
- Primidone, therapeutic monitoring of, 487-489
- Procainamide, therapeutic monitoring of, 507-509  
toxic effects, 508-509
- Propranolol, therapeutic monitoring of, 514-516  
toxic effects, 515
- Protriptyline, therapeutic monitoring of, 541-544
- Psychosis, drug therapy for, 547-557
- QUALITY control, in therapeutic drug monitoring, 448
- Quinidine, therapeutic monitoring of, 503-507  
toxic effects, 505-506
- RADIOIMMUNOASSAY(s), in therapeutic drug monitoring, 453-455
- Rheumatic disease, drug therapy for, 567-573
- Rifampin, toxic effects, 595
- SALICYLATE(s), therapeutic monitoring of, 567-573  
toxic effects, 570-572
- Schizophrenia, drug therapy for, 547-557

- Seizure(s), drug therapy for, 479–500
- Specimen(s), handling, 442
- Spectrophotometry, in monitoring acetaminophen, 578
- in monitoring salicylate, 573
  - in monitoring theophylline, 566
- Sulfonamide(s), toxic effects, 593–594
- Superinfection, laboratory diagnosis, 595–596
- 
- TECHNOLOGY, laboratory, in therapeutic drug monitoring, 451–466
- Testing, laboratory. *See* *Laboratory tests* or under specific method.
- Tetracycline(s), toxic effects, 589–590
- Theophylline, therapeutic monitoring of, 559–565
- toxic effects, 565–566
- Therapeutic drug monitoring, 439–597. *See* also under specific drugs.
- chromatographic methods in, 460–463
  - confounding factors in, 469–478
  - immunoassays in, 453–460
  - organization of laboratory service for, 439–450
  - pharmacokinetic and pharmacodynamic principles, 467–478
  - quality control, 448
- Thiocyanate, therapeutic monitoring of, 535–536
- Thioridazine, therapeutic monitoring of, 553–554
- Toxicity, drug. *See* under specific drugs.
- Tricyclic antidepressant(s), therapeutic monitoring of, 455, 541–544
- Trimethoprim, toxic effects, 594
- 
- VALPROIC acid, therapeutic monitoring of, 486–487
- Vancomycin, toxic effects, 591–592